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CASE REPORT
Parafoveolar retinoblastoma regression 
with foveal preservation following intra-arterial 
chemotherapy documented on hand-held 
optical coherence tomography in a newborn
Vera Yarovaya, Kareem Sioufi and Carol L. Shields*
Abstract 
Background: Optical coherence tomography (OCT) has become an invaluable tool in retinoblastoma management, 
providing submillimeter visualization of tumor control following treatment. Herein, we document OCT-detection of a 
subtle tumor recurrence, allowing early intervention and achieving foveal microanatomy preservation.
Case presentation: A 3-week-old girl was diagnosed with bilateral familial retinoblastoma, classified as group D in 
the right eye (OD) and group B in the left eye (OS), and treated with intravenous chemoreduction. At 6-months fol-
low-up, the right eye was under control, but the left eye revealed a subtle juxtafoveal tumor recurrence, documented 
on handheld OCT (HH-OCT) and measuring 2750 µm in diameter and 792 µm in thickness. Treatment with intraarte-
rial chemotherapy (IAC) using 1 cycle of melphalan 5 mg was performed and complete tumor control was achieved, 
leaving a flat, concave scar 663 µm from the intact foveola and measuring 2750 µm in diameter and 120 µm in thick-
ness. Foveal microanatomy OS was preserved on HH-OCT. The findings remained stable at 2 years following IAC.
Conclusions: HH-OCT is an important tool in retinoblastoma management. In this case, HH-OCT allowed for early 
detection of retinoblastoma recurrence, before foveal invasion. Following treatment with IAC, complete tumor regres-
sion was noted and foveal microanatomy remained intact.
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Background
Optical coherence tomography (OCT) has become an 
invaluable tool for in vivo evaluation of the microstruc-
ture of the retina and choroid. This technology employs 
light scatter to create a 2-dimensional cross-sectional 
image of the human fundus, initially described by Huang 
et  al. [1]. With advancements in technology and devel-
opment of spectral-domain (SD-OCT), high resolution 
in  vivo evaluation of retinal microanatomy in healthy 
and diseased eyes now approaches resolution of tis-
sue histology. The subspecialty of ocular oncology has 
incorporated SD-OCT into practice for the study of the 
structure of various retinal, choroidal, optic disc, and 
scleral tumors and their relationship to other structures 
[2]. Handheld OCT (HH-OCT), a portable, SD-OCT 
unit that can be used in the operating room, has become 
a crucial diagnostic tool in pediatric retinal diseases as it 
provides accurate localization of disease processes and is 
completely noninvasive [3]. HH-OCT is also used in the 
management of retinoblastoma, providing submillimeter 
visualization of tumor development and regression, far 
beyond the detection by ophthalmoscopy. In addition, 
this technology allows for detection of invisible tumors 
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Herein, we report the case of a 3-week-old girl with 
bilateral familial retinoblastoma treated with systemic 
chemoreduction. Tumor recurrence was confirmed on 
HH-OCT and was subsequently controlled with intraar-
terial chemotherapy (IAC). Documentation with HH-
OCT allowed accurate monitoring of the tumor as well 
as the foveola.
Case presentation
A 3-week-old girl, with a family history of maternal 
unilateral retinoblastoma, presented for evaluation of 
leukocoria right eye (OD). On examination, visual acu-
ity was fix and follow in both eyes (OU) and intraocular 
pressures were normal OU. External examination docu-
mented obvious leukocoria OD. Fundus evaluation OD 
revealed a white macular tumor measuring 16.0  mm in 
largest basal dimension and 6.1  mm in thickness, and 
with overlying mild vitreous seeding and surrounding 
extensive serous retinal detachment. Fundus evaluation 
of the left eye (OS) detected a solitary mass measuring 
2.0  mm in basal dimension and 1.0  mm in thickness, 
located within 2.0 mm from the foveola. A diagnosis of 
bilateral familial retinoblastoma, group D OD and group 
B OS, was rendered and treatment with intravenous 
chemoreduction (CRD) using vincristine, etoposide, and 
carboplatin was initiated. Following therapy with indi-
vidual tumor consolidation, all retinoblastomas were 
regressed.
At 6-months follow-up, the right eye remained under 
control, but the left eye revealed a subtle recurrence of 
the juxtafoveal tumor (Fig. 1a) and HH-OCT (iVue Opto-
vue, Fremont, CA) revealed an intact macula with adja-
cent tumor recurrence (Fig.  1b), measuring 2750  µm 
in diameter and 792  µm in thickness. The recurrence 
was 615  µm from the foveola. Treatment with intraar-
terial chemotherapy (IAC) using Melphalan 5  mg was 
Fig. 1 Documentation of retinoblastoma control using spectral domain hand-held optical coherence tomography (HH-OCT). Following 6 cycles 
of intravenous chemotherapy for bilateral retinoblastoma, the left eye demonstrated small dome-shaped, outer retinal tumor recurrence (a) of 
2750 µm in basal dimension and 792 µm thickness in the parafoveolar region, documented on HH-OCT (b) and with adjacent shallow subretinal 
fluid. The mass was 615 µm from the foveola. Following 1 cycle of intraarterial chemotherapy, the tumor showed complete regression (c) and HH-
OCT (d) documented a concave scar of 120 µm in thickness and located 663 µm from foveola. There was OCT light transmission through atrophic 
retinal pigment epithelial accentuating the underlying thin choroid. The foveola remained intact
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performed and complete tumor control was achieved 
with 1 cycle (Fig. 1c), leaving a concave scar of 2750 µm 
in diameter and 120  µm in thickness, located 663  µm 
from the foveola. In addition, there was underlying cho-
roidal thinning and preservation of the foveal microanat-
omy documented by HH-OCT OS (Fig. 1d). The findings 
remained stable on last follow-up at 2  years following 
IAC.
Discussion and conclusions
Chemotherapy is a first-line globe-sparing therapy for ret-
inoblastoma and can be delivered through intravenous, 
intraarterial, sub-Tenon fascia, and intravitreal routes 
[7]. IAC has assumed a major role in retinoblastoma 
management, achieving globe salvage and resolution of 
retinal detachment with minimal systemic toxicities [8, 
9]. Studies have documented that IAC can be employed 
as a primary treatment or secondary (rescue) treatment 
for eyes that fail alternative therapies [10]. Overall, IAC 
achieves retinoblastoma control with globe salvage in 72% 
of eyes as a primary therapy and 62% of eyes when used 
as secondary therapy [10]. Our patient had initial treat-
ment with intravenous chemotherapy and was secondar-
ily treated with IAC, achieving immediate tumor control, 
and with foveolar preservation, despite the proximity of 
the tumor within 615 µm to the foveola.
Imaging of retinoblastoma includes digital wide-field 
fundus photography, fluorescein angiography,  ultra-
sonography, and now HH-OCT. In this case we used 
the stand-mounted iVue Optovue (Optovue, Freemont, 
CA) to capture the tumor. The iVue provides up to 21° 
field of view and can be mounted on a wheeled stand 
which offers stability when acquiring OCT images dur-
ing examination under anesthesia. HH-OCT scans using 
iVue can be captured with minimal pupillary dilation but 
a fully dilated pupil yields better results. HH-OCT pro-
vides precise submillimeter tumor documentation within 
the retina and even into the choroid [4, 11, 12]. In fact, 
HH-OCT can provide detection of “invisible” retinoblas-
toma, first reported by Saktanasate et al. in which a sub-
clinical tumor was coincidentally captured on HH-OCT 
in the macular region, and localized to the outer nuclear 
layer [4]. Berry et  al. later demonstrated the use of SD-
OCT to identify subclinical retinoblastoma, estimating 
that this technology could allow earlier diagnosis and 
treatment with less treatment-related damage to ocular 
structures and more careful surveillance [11]. Soliman 
et al. evaluated the use of HH-OCT in 63 eyes and found 
that in 339 HH-OCT sessions 92% were informative, of 
which OCT directed diagnosis in 16% and treatment 
in 58% [13]. They also noted that OCT influenced pre-
OCT treatment plans in 15% of all OCT sessions. In this 
case, we confirmed clinical suspicion of recurrence using 
HH-OCT documenting a homogenous dome-shaped 
intraretinal mass with inner retinal draping over the solid 
tumor. We subsequently documented complete tumor 
response to IAC with OCT-evidence of concave regres-
sion and preservation of the foveola, despite the parafo-
veolar tumor location.
In our case, tumor recurrence was detected early with 
HH-OCT, allowing intervention with IAC for complete 
tumor regression and preservation of the foveal micro-
anatomy. In most cases, 3 cycles of IAC are necessary for 
tumor control, but given the submillimeter recurrence, 
only 1 cycle was necessary to achieve control with no fur-
ther recurrence on 2-year follow-up.
In summary, HH-OCT is an invaluable tool in retino-
blastoma management, providing information that aids 
treatment decisions, particularly in juxtafoveal tumors. 
The role of HH-OCT in retinoblastoma management 
includes detection of subclinical new tumors, monitoring 
of tumor regression, detection of small tumor recurrence, 
and judgment of foveolar microanatomy with estimation 
of visual potential in a preverbal child.
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